IMNM - CIK 0001472012
Immunome Inc. trades as IMNM and has a market capitalization of $2.05 B, making it the #2082 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $6.94M, down 23.2% from the prior year and net income of -$212.39M. This page tracks Immunome Inc. through 416 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -761.9% to -3060.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-19 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-12 |
| Annual report to shareholders | ARS | 2026-04-24 |
The largest companies sharing Immunome Inc.'s SEC industry classification (pharmaceutical preparations).
Immunome Inc. (IMNM) has a market capitalization of $2.05 B as of 2026-06-10, ranking #2082 among US-listed companies.
Immunome Inc. reported revenue of $6.94M for fiscal year 2025, a decrease of 23.2% year over year.
In its latest fiscal year Immunome Inc. reported a net loss of $212.39M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.